Navigation Links
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form
Date:7/11/2011

LAUSANNE, Switzerland, July 11, 2011 /PRNewswire/ --


EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company, announces that US patent 7,964,212 was issued on June 21, 2011, enhancing the protection of EX101.

This patent grants significant additional Intellectual Property concerning the EffRx Lead Program, EX101 (70 mg effervescent alendronate for the treatment of osteoporosis).

The extended range of intellectual property in this patent protects effervescent formulations of all the orally administered bisphosphonate osteoporosis medications including risedronate and ibandronate, when delivered in the highly buffered EX101 formulation. The formulation is unique in that it delivers the bisphosphonate to the stomach in a proprietary buffered solution which prevents exposure of the stomach or esophagus to strongly acidified bisphosphonate forms, which are believed to be damaging forms of this drug class.  

Additional claims related to the buffering composition and method of manufacturing were also granted.

An NDA for EX101 has been filed by the FDA. Nycomed has licensed EX101 for territories outside the United States, Canada and Japan, and the product is in registration in many countries.

"There are more and more reports around the world that generic alendronate products have even more GI-side effect problems and thereby less patient compliance than branded bisphosphonate products. We strongly believe that EX101 fills an unmet need of patients, doctors, and payers around the world since poor compliance leads to escalating health costs due to osteoporosis related fractures" stated Christer Rosén, Chairman and CEO.

About EffRx

EffRx is a privately held drug delivery technology company specializing in the utilization of proprietary effervescent technology to develop formulations that improve efficiency, compliance and convenience of existing prescription drugs.

For additional information please visit the EffRx website http://www.effrx.com  

Contacts:
Christer Rosén
Chairman and CEO
crosen@effrx.com
+41-79-963-66-00

Marshall Hayward
CSO
mhayward@effrx.com
+41-79-963-66-04



'/>"/>
SOURCE EffRx Pharmaceuticals S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
2. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. Rosetta Genomics Announces One-For-Four Reverse Stock Split
5. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
6. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
7. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
8. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
9. Tengion Announces Leadership Transition
10. The Olive Branch Fund Announces Funding Award to Harvard Researcher
11. Verenium Announces Signing of Lease for New Office and Lab Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):